Noise-Reduction and Sensitivity-Enhancement of a Sleeping Beauty-Based Tet-On System

Genes (Basel). 2022 Sep 20;13(10):1679. doi: 10.3390/genes13101679.

Abstract

Tetracycline-inducible systems are widely used control elements for mammalian gene expression. Despite multiple iterations to improve inducibility, their use is still compromised by basal promoter activity in the absence of tetracyclines. In a mammalian system, we previously showed that the introduction of the G72V mutation in the rtTA-M2 tetracycline activator lowers the basal level expression and increases the fold-induction of multiple genetic elements in a long chimeric antigen receptor construct. In this study, we confirmed that the G72V mutation was effective in minimising background expression in the absence of an inducer, resulting in an increase in fold-expression. Loss of responsiveness due to the G72V mutation was compensated through the incorporation of four sensitivity enhancing (SE) mutations, without compromising promoter tightness. However, SE mutations alone (without G72V) led to undesirable leakiness. Although cryptic splice site removal from rtTA did not alter the inducible control of the luciferase reporter gene in this simplified vector system, this is still recommended as a precaution in more complex multi-gene elements that contain rtTA. The optimized expression construct containing G72V and SE mutations currently provides the best improvement of fold-induction mediated by the rtTA-M2 activator in a mammalian system.

Keywords: gene regulation; sleeping beauty transposon; tetracycline inducible promoter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Mammals / genetics
  • RNA Splice Sites
  • Receptors, Chimeric Antigen* / genetics
  • Tetracycline* / pharmacology
  • Tetracyclines / pharmacology
  • Trans-Activators / genetics

Substances

  • Tetracycline
  • Receptors, Chimeric Antigen
  • RNA Splice Sites
  • Trans-Activators
  • Tetracyclines
  • Anti-Bacterial Agents

Grants and funding

This work was funded by the Marsden Fund New Zealand UOO1806 and a Health Research Council Explorer Grant 20/768.